$26.3 Million is the total value of CAXTON CORP's 9 reported holdings in Q3 2023. The portfolio turnover from Q2 2023 to Q3 2023 was 57.1% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| SVRA | Sell | SAVARA INC | $12,525,416 | -21.8% | 3,313,602 | -33.5% | 47.59% | +2.9% |
| XERIS BIOPHARMA HOLDINGS INC | $10,493,971 | -29.0% | 5,641,920 | 0.0% | 39.87% | -6.5% | ||
| RZLT | REZOLUTE INC | $1,741,036 | -33.3% | 1,318,967 | 0.0% | 6.61% | -12.2% | |
| New | MOLECULAR TEMPLATES INC | $864,993 | – | 136,866 | +100.0% | 3.29% | – | |
| New | APOGEE THERAPEUTICS INC | $265,653 | – | 12,472 | +100.0% | 1.01% | – | |
| CMPX | Buy | COMPASS THERAPEUTICS INC | $170,942 | +23.7% | 86,773 | +99.6% | 0.65% | +62.7% |
| ACRS | New | ACLARIS THERAPEUTICS INC | $133,387 | – | 19,473 | +100.0% | 0.51% | – |
| ALLK | Buy | ALLAKOS INC | $111,978 | +44.8% | 49,329 | +178.2% | 0.42% | +90.6% |
| ELEV | Buy | ELEVATION ONCOLOGY INC | $14,453 | -56.2% | 21,813 | +0.4% | 0.06% | -42.1% |
| MTEM | Exit | MOLECULAR TEMPLATES INC | $0 | – | -2,052,991 | -100.0% | -2.84% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| MOLECULAR TEMPLATES INC | 24 | Q2 2023 | 30.7% |
| STRONGBRIDGE BIOPHARMA PLC | 22 | Q3 2021 | 73.1% |
| GARRISON CAP INC | 18 | Q3 2020 | 9.9% |
| BERKSHIRE HATHAWAY INC DEL | 17 | Q3 2019 | 5.8% |
| EIGER BIOPHARMACEUTICALS INC | 17 | Q3 2022 | 1.7% |
| AGILE THERAPEUTICS INC | 16 | Q1 2018 | 55.5% |
| KALA PHARNACEUTICALS INC | 16 | Q4 2021 | 17.6% |
| CM FIN INC | 16 | Q1 2019 | 7.8% |
| SYNTA PHARMACEUTICALS CORP | 15 | Q2 2016 | 99.9% |
| CTI BIOPHARMA CORP | 14 | Q4 2021 | 8.7% |
View CAXTON CORP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Addex Therapeutics Ltd. | February 14, 2023 | 718,849 | 0.9% |
| Cardiff Oncology, Inc. | February 14, 2023 | 983,607 | 2.2% |
| Rezolute, Inc. | February 14, 2023 | 1,860,518 | 5.0% |
| Xeris Biopharma Holdings, Inc. | February 14, 2023 | 5,973,324 | 4.4% |
| CTI BIOPHARMA CORP | February 14, 2022 | 2,239,300 | 2.3% |
| Sierra Oncology, Inc. | February 14, 2022 | 1,119,322 | 7.0% |
| Strongbridge Biopharma plcSold out | January 05, 2022 | 0 | 0.0% |
| SUNESIS PHARMACEUTICALS INCSold out | February 16, 2021 | 0 | 0.0% |
| Alcentra Capital Corp | February 14, 2020 | 1,005,000 | 7.8% |
| Garrison Capital Inc. | February 14, 2020 | 1,223,096 | 7.6% |
View CAXTON CORP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
View CAXTON CORP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.